Ventyx Biosciences, Inc.
ventyxbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2026.
10-Q for Q3 FY2025, filed Nov 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops oral small-molecule drug candidates for patients with autoimmune, inflammatory, and neurodegenerative diseases.
10-K for FY2024, filed Feb 27, 2025Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Feb 27, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 6, 2025
−$22.8MView ↗
- ▼ −35% (Loss)
- vs −$35.2M in Q3 FY2024
Pipeline emphasis
The older report led with a kinase inhibitor and framed its pipeline around inflammatory and immune diseases; the latest report leads with inflammasome inhibitors for systemic, cardiovascular, and neurodegenerative diseases, while retaining bowel-disease candidates.
10-K for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Feb 27, 2025
Narrower kinase program
The older report described the kinase inhibitor for a range of immune diseases; the latest focuses on Crohn’s disease and says further development will not receive significant internal resources.
10-K for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Feb 27, 2025Maximize the value of VTX958, our selective TYK2 inhibitor, by developing it across multiple inflammatory and autoimmune indications. Our…View ↗
Loading...
